The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen reported key milestones for its ophthalmology pipeline, including provisional approval and priority designation in the Bahamas for OCU400, as well as a new licensing agreement in the MENA region.
The company also initiated Phase 3 dosing for OCU410 and shared topline results from OCU400 Phase 3 are anticipated in the first quarter of 2027. Ocugen ended the quarter with $84.6 million in cash.
View post on X Loading...
Earlier, Ocugen launched a modifier gene therapy using master regulator genes to address major blindness diseases through network influence, as detailed in a previous announcement. The company also signed an OCU400 licensing agreement with Roots Pharmaceutical for the MENA region with up to $259 million in potential milestones and royalties, according to terms released last year. These steps have supported Ocugen's ongoing expansion of its ophthalmology pipeline.